If you've been watching Moderna (MRNA) this week, you might have done a double-take. The stock has staged a dramatic comeback, adding billions in market value and delivering a windfall for investors in a leveraged ETF tied to the biotech company. The reason? Traders are betting on a favorable regulatory outcome for its seasonal flu vaccine.
Shares of Moderna climbed nearly 60% over the past five trading sessions, boosting the company's market capitalization by roughly $6.2 billion to about $24 billion, according to Trefis. The rally accelerated after the U.S. Food and Drug Administration released briefing documents ahead of a closely watched advisory committee meeting on Moderna's mRNA-based seasonal flu vaccine, mFlusiva.
The move has been even more pronounced in the Defiance Daily Target 2X Long MRNA ETF (MRNX), which seeks to deliver twice the daily performance of Moderna stock. The fund gained more than 60% over the same five-day period, highlighting how leveraged single-stock ETFs can amplify gains when sentiment shifts sharply.
FDA Review Revives Investor Optimism
Investors appeared encouraged by the FDA's briefing materials, which struck a largely balanced tone ahead of a vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on whether the benefits of mFlusiva outweigh its risks for adults aged 50 and older.
The development marks a significant turnaround from February, when the FDA issued a surprise refuse-to-file letter for the vaccine application, citing concerns about the comparator trial used in Moderna's studies. The agency later reversed course, and the latest documents noted some evidence gaps in older and immunocompromised populations but identified no major deficiencies.
The regulatory update has fueled hopes that Moderna may finally be able to expand beyond its COVID-19 vaccine franchise and establish a broader respiratory vaccine portfolio.
Pipeline Launches Come Into Focus
Adding to the optimism, Moderna recently announced an internal reorganization and appointed Ester Banque as chief commercial officer as the company prepares for several potential product launches over the next few years.
Among the most anticipated candidates are a flu/COVID combination vaccine and a norovirus vaccine, both expected to reach the market in 2027 or 2028 if approved.
The renewed focus on commercialization is helping investors reassess Moderna's long-term growth prospects after years of declining pandemic-related revenue.
What It Means For ETF Investors
While MRNX has emerged as one of the biggest beneficiaries of Moderna's rally, the company's resurgence could also attract attention from investors in broader biotechnology funds such as the iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and ARK Genomic Revolution ETF (ARKG), all of which have exposure to innovative drug developers and biotechnology companies.
For now, Moderna's sharp rebound has become a reminder of how quickly sentiment can change in biotech, and how leveraged ETFs can magnify those moves when investors pile into a high-conviction catalyst trade.
